144 related articles for article (PubMed ID: 9123032)
1. Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation.
Kaden J; May G; Strobelt V; Groth J; Müller P
Transplant Proc; 1997; 29(1-2):344-7. PubMed ID: 9123032
[No Abstract] [Full Text] [Related]
2. Intraoperative high-dose anti-T-lymphocyte globulin bolus in addition to triple-drug therapy improves kidney graft survival.
Kaden J; May G; Müller P; Groth J; Strobelt V; Eger E; Wohlfahrt L
Transplant Proc; 1995 Feb; 27(1):1060-1. PubMed ID: 7878804
[No Abstract] [Full Text] [Related]
3. Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation.
Kaden J; Strobelt V; May G
Transplant Proc; 1998 Dec; 30(8):4011-4. PubMed ID: 9865279
[No Abstract] [Full Text] [Related]
4. Long-term results and risk factors of quadruple immunosuppression in renal transplantation.
Hiesse C; Kriaa F; Eschwege P; Boubenider S; Marchand S; Benoit G; Charpentier B
Transplant Proc; 1999; 31(1-2):1111-2. PubMed ID: 10083496
[No Abstract] [Full Text] [Related]
5. Excellent long-term survival of low-risk, first renal allografts using cyclosporine/azathioprine double therapy.
Faull RJ; Bannister KM; Russ GR; Mathew TH; Clarkson AR
Transplant Proc; 1999; 31(1-2):1155-6. PubMed ID: 10083516
[No Abstract] [Full Text] [Related]
6. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.
Fischer L; Sterneck M; Gahlemann CG; Malago M; Rogiers X; Broelsch CE
Transplant Proc; 2000 Nov; 32(7):2125-7. PubMed ID: 11120098
[No Abstract] [Full Text] [Related]
7. Current advantage of FK 506 in cadaveric kidney transplantation.
Ciancio G; Rosen A; Loreto-Grand B; Burke G; Siquijor A; Luque C; Esquenazi V; Miller J
Transplant Proc; 1996 Apr; 28(2):1000-1. PubMed ID: 8623207
[No Abstract] [Full Text] [Related]
8. Low incidence of acute rejection in kidney grafts treated with initial quadruple therapy: a retrospective analysis comparing two ATGs.
Civati G; Minetti E; Busnach G; Perego A; Brando B; Broggi ML; Sansalone V; Forti D
Transplant Proc; 1998 Jun; 30(4):1343-5. PubMed ID: 9636546
[No Abstract] [Full Text] [Related]
9. Non-heart-beating donor kidney transplantation under tacrolimus immunosuppression.
Toda F; Tanabe K; Tokumoto T; Ishikawa N; Koga S; Ito S; Yagisawa T; Toma H
Transplant Proc; 2000 Nov; 32(7):1726-9. PubMed ID: 11119909
[No Abstract] [Full Text] [Related]
10. Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients.
Kuypers DR; Evenepoel P; Maes BD; Coosemans W; Pirenne J; Vanrenterghem YF
Transplant Proc; 2002 Jun; 34(4):1164-70. PubMed ID: 12072305
[No Abstract] [Full Text] [Related]
11. Preoperative ATG bolus treatment increase CsA sensitivity of peripheral blood lymphocytes (PBLS) in renal transplant patients.
Abudher MN; Moorhead JF; Fernando ON; Varghese Z
Transplant Proc; 1999 Dec; 31(8):3361-4. PubMed ID: 10616507
[No Abstract] [Full Text] [Related]
12. Low incidence of rejection after synchronous pancreas-kidney transplantation with Neoral.
Cattral MS; Hemming AW; Greig PD; Rowsell C; Chari R; Wright E; Donat D; Cole E; Levy GA
Transplant Proc; 1998 Aug; 30(5):1946. PubMed ID: 9723346
[No Abstract] [Full Text] [Related]
13. Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction.
Nampoory MR; Abdulhalim M; Johny KV; Al-Jawad Donia FA; Nair MP; Said T; Homoud H; Samhan M; Al-Mousawi M
Transplant Proc; 2002 Nov; 34(7):2916-9. PubMed ID: 12431656
[No Abstract] [Full Text] [Related]
14. The ATG bolus does not induce a persistent inversion of the CD4/8 ratio.
Kaden J; Eichler S; May G; Strobelt V
Transplant Proc; 2002 Sep; 34(6):2379-81. PubMed ID: 12270446
[No Abstract] [Full Text] [Related]
15. Induction therapy with bolus ATG increases cyclosporine sensitivity in renal transplant recipients.
Varghese Z; Abudher MN; Fernando ON; Moorhead JF
Transplant Proc; 2001 May; 33(3):2251-3. PubMed ID: 11377518
[No Abstract] [Full Text] [Related]
16. Kidney transplantation at extremes of age: CsA eliminates the increased risk in recipients < or = 5 or > or = 55 years.
MacDonell RC; Van Buren DH; Richie RE; Johnson HK; Nylander WA; Helderman JH; Ynares CM; Trusler LA; Green WF; Crowe DA
Transplant Proc; 1994 Oct; 26(5):2518-21. PubMed ID: 7940774
[No Abstract] [Full Text] [Related]
17. Kidney transplantation in pediatric population.
Mota C; Henriques C; Sarmento M; Pereira E; Xavier E; Pereira M
Transplant Proc; 1994 Oct; 26(5):2768-70. PubMed ID: 7940872
[No Abstract] [Full Text] [Related]
18. Increasing incidence of steroid resistant rejection in kidney transplantation.
Arrazola L; Sozen H; Humar A; Papalois V; Uknis M; Matas AJ
Transplant Proc; 2000 Nov; 32(7):1767. PubMed ID: 11119926
[No Abstract] [Full Text] [Related]
19. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.
Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP
Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031
[No Abstract] [Full Text] [Related]
20. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation.
Kliem V; Radermacher J; Hiss M; Pethig M; Burg M; Brunkhorst R
Transplant Proc; 1999 Nov; 31(7A):37S-40S. PubMed ID: 10576041
[No Abstract] [Full Text] [Related]
[Next] [New Search]
